公开(公告)号：US20100160647A1

公开(公告)日：2010-06-24

申请号：US12644378

申请日：2009-12-22

申请人： Kazuyuki OHMOTO ,  Satoshi ITADANI ,  Yoshisuke NAKAYAMA ,  Jun TAKEUCHI ,  Manabu FUJITA

发明人： Kazuyuki OHMOTO ,  Satoshi ITADANI ,  Yoshisuke NAKAYAMA ,  Jun TAKEUCHI ,  Manabu FUJITA

IPC分类号： C07D209/12

CPC分类号： C07D209/18

摘要： As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

摘要翻译： 作为具有有效的口服活性和持久的cysLT1 / cysLT2受体拮抗活性的化合物，式（I）化合物：其对cysLT1 / cysLT2受体具有强的拮抗活性，并且即使在例如 因此可用作预防和/或治疗各种疾病的口服药物，例如呼吸系统疾病（例如哮喘（支气管哮喘等），慢性阻塞性肺病（COPD），肺部 肺气肿，慢性支气管炎，肺炎（间质性肺炎等），严重急性呼吸综合征（SARS），急性呼吸窘迫综合征（ARDS），呼吸暂停综合征，过敏性鼻炎，鼻窦炎（急性鼻窦炎，慢性鼻窦炎等），肺纤维化 ，咳嗽（慢性咳嗽等）等）。